Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin plus radiotherapy in retroperitoneal soft tissue sarcoma
2024-518199-30-00Phase 2Authorised
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of trabectedin in soft tissue sarcoma (STS), retroperitoneal sarcoma (RPS), Liposarcoma and 1 more (4 cohorts), sponsored by Spanish Group for Research on Sarcoma. Primary endpoints: Maximum tolerated dose or recommended phase II dose, RECIST response in cohorts A and B and 2 more. Planned start Nov 2024; status: authorised.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)retroperitoneal sarcoma (RPS)Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on 2024-518199-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518199-30-00.